Prognose

Das durchschnittliche Kursziel der Analysten beträgt +45,04€(+11,13%). Der Median liegt bei +43,61€(+7,60%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

QGEN Stock Rises in After Market Following Partnership With Incyte
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.» Mehr auf zacks.com
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofi.» Mehr auf businesswire.com
Should You Add QIAGEN Stock to Your Portfolio for Now?
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.» Mehr auf zacks.com

Im letzten Quartal hatte Qiagen NV einen Umsatz von 446,89 Mio€ und ein Nettoeinkommen von 83,89 Mio€